Status:
UNKNOWN
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Lead Sponsor:
Han weidong
Conditions:
Lymphomas
Eligibility:
All Genders
18-90 years
Brief Summary
To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Detailed Description
Autologous CIK transfusion within 3 days post CD20 antibody treatment.
Eligibility Criteria
Inclusion
- \- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy
Exclusion
- \- to refuse the therapy and need not tolerate the therapy
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01828008
Start Date
April 1 2013
End Date
May 1 2015
Last Update
April 10 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.